131 related articles for article (PubMed ID: 36152905)
1. Interleukin 13 receptor alpha 2 (IL13Rα2): Expression, signaling pathways and therapeutic applications in cancer.
Jaén M; Martín-Regalado Á; Bartolomé RA; Robles J; Casal JI
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188802. PubMed ID: 36152905
[TBL] [Abstract][Full Text] [Related]
2. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
Bartolomé RA; Jaén M; Casal JI
Br J Cancer; 2018 Oct; 119(8):940-949. PubMed ID: 30318506
[TBL] [Abstract][Full Text] [Related]
3. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
[TBL] [Abstract][Full Text] [Related]
4. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.
Papageorgis P; Ozturk S; Lambert AW; Neophytou CM; Tzatsos A; Wong CK; Thiagalingam S; Constantinou AI
Breast Cancer Res; 2015 Jul; 17(1):98. PubMed ID: 26208975
[TBL] [Abstract][Full Text] [Related]
5. Schnurri-3 drives tumor growth and invasion in cancer cells expressing interleukin-13 receptor alpha 2.
Bartolomé RA; Martín-Regalado Á; Pintado-Berninches L; Robles J; Ramírez-González MÁ; Boukich I; Sanchez-Gómez P; Balyasnikova IV; Casal JI
Cell Death Dis; 2023 Nov; 14(11):742. PubMed ID: 37963919
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
He H; Xu J; Nelson PS; Marshall FF; Chung LW; Zhau HE; He D; Wang R
Prostate; 2010 Jun; 70(9):993-1001. PubMed ID: 20166133
[TBL] [Abstract][Full Text] [Related]
8. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.
Balyasnikova IV; Wainwright DA; Solomaha E; Lee G; Han Y; Thaci B; Lesniak MS
J Biol Chem; 2012 Aug; 287(36):30215-27. PubMed ID: 22778273
[TBL] [Abstract][Full Text] [Related]
9. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
10. IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.
Xie M; Wu XJ; Zhang JJ; He CS
Oncotarget; 2015 Oct; 6(32):32902-13. PubMed ID: 26418721
[TBL] [Abstract][Full Text] [Related]
11. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
12. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.
Jarboe JS; Johnson KR; Choi Y; Lonser RR; Park JK
Cancer Res; 2007 Sep; 67(17):7983-6. PubMed ID: 17804706
[TBL] [Abstract][Full Text] [Related]
13. A novel target anti-interleukin-13 receptor subunit alpha-2 monoclonal antibody inhibits tumor growth and metastasis in lung cancer.
Raza G; Yunus FU; Mangukiya HB; Merugu SB; Mashausi DS; Zeling W; Negi H; Zhou B; Roy D; Wu Z; Li D
Int Immunopharmacol; 2021 Jan; 90():107155. PubMed ID: 33243603
[TBL] [Abstract][Full Text] [Related]
14. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
15. IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases.
Márquez-Ortiz RA; Contreras-Zárate MJ; Tesic V; Alvarez-Eraso KLF; Kwak G; Littrell Z; Costello JC; Sreekanth V; Ormond DR; Karam SD; Kabos P; Cittelly DM
Clin Cancer Res; 2021 Nov; 27(22):6209-6221. PubMed ID: 34544797
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract][Full Text] [Related]
17. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
[TBL] [Abstract][Full Text] [Related]
18. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.
Liang R; Wu C; Liu S; Zhao W
Drug Deliv; 2022 Dec; 29(1):1620-1630. PubMed ID: 35612318
[TBL] [Abstract][Full Text] [Related]
19. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
20. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
